Ting-Wan Lin
Director of Business Development & Project Manager GenomeFrontier Therapeutics
Dr. Ting-Wan Lin is Director of Business Development and Project Management at GenomeFrontier Therapeutics, a clinical-stage biotechnology company pioneering next-generation virus-free gene and cell therapies. She leads global business development and strategic partnership initiatives supporting the advancement of GenomeFrontier’s Quantum Engine™ platform and innovative CAR-T programs.
Seminars
Thursday 12th November 2026
Early Clinical Validation of GF-CART01: A Non-Viral Dual-Targeting CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies
11:30 am
- Introducing Quantum Engine for non-viral gene therapy
- Describing the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Presenting preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell hematologic cancers
